RU58841, a potential hair loss treatment, was not commercialized due to marketability issues and lack of long-term safety data. Concerns about its formulation and delivery methods further complicate its use.
The conversation discusses skepticism around claims that dutasteride worsens hair loss, with some users suggesting misinformation or panic during shedding as reasons for such claims. One user shared their negative experience with dutasteride, including increased sebum production and hair loss, and is now considering a higher dose of oral minoxidil after stopping dutasteride.
The efficacy of degrading the androgen receptor through dermal application in DP cells, a delivery system for topical drugs that involves dissolving microneedles, and rosemary oil as an alternative anti-androgen.
Treating Seborrheic Dermatitis, a fungal scalp condition which can cause hair loss. Treatments discussed include antifungal shampoos, cold showers, exfoliating the scalp, taking Vitamin D, and stimulating the prostate through the anus.
Jordan-Iliad has been using a combination of finasteride, minoxidil, stemoxydine, microneedling, saw palmetto, peppermint and jojoba oils, ketoconazole shampoo, and Purador shampoo/conditioner for 3 months to treat their hair loss with stunning results. They have also recently started taking oral minoxidil 1.25mg/day in hopes of achieving even better results over the next 3 months.
This conversation discusses the potential benefits of using oral minoxidil and finasteride to treat hair loss, with some users sharing their own experiences in taking the medications. Others express concerns about the safety of these treatments.
Researchers finding that microRNA can potentially regrow 90% of lost hair, and the challenges involved in moving this research forward to human trials. Various treatments for hair loss, such as finasteride and minoxidil, have been discussed.
N-Acetyl-Cysteine (NAC) was found to improve hair parameters in men with early-onset androgenetic alopecia, showing increased terminal hair count and decreased vellus hair count, with good tolerability. NAC, used alone or with minoxidil, may help due to its antioxidant properties, though its effectiveness can vary among individuals.
Kintor's Pyrilutamide results for hair loss treatment will be released soon. The treatment may replace current treatments like finasteride and minoxidil without systemic side effects.
Minoxidil and finasteride are discussed for hair loss, with concerns about minoxidil's heart-related side effects. New treatments like PP405 are met with skepticism, often humorously noted as always being "five years away."
PP405 may reactivate dormant hair follicles but won't replace hair transplants or resurrect dead follicles. Its effectiveness, cost, and impact compared to treatments like minoxidil and finasteride are uncertain.
PP405 is a new topical treatment for hair loss, showing promise in trials but still requires finasteride for maintenance. There is skepticism about its effectiveness and safety, with concerns about needing finasteride to maintain results.
KX-826/pyrilutamide is undergoing an additional one-year safety and efficacy trial in China after a six-month study. Some participants speculate on the reasons for the extended trial and discuss the potential of other treatments.
Hair loss treatments, such as Dutasteride, Minoxidil, and Finasteride. Advice is given to give the medications time to work and to consider a Hair Transplant in order to fill any gaps caused by continuing hair loss.
ET-02, a new hair loss treatment, shows promising results with a 6-fold increase in hair count, potentially outperforming minoxidil by activating stem cells in hair follicles. Further trials are ongoing to confirm its efficacy and safety, with potential market release in the future.
A user applied the 8T3 product for hair loss, targeting LPP and AGA, and plans to update on its effectiveness. The product uses a saline buffered phosphate vehicle, suitable for those intolerant to ethanolic vehicles.
Stemson Therapeutics announced a breakthrough in hair growth technology using stem cells. Users discussed the potential high cost and skepticism about the treatment's accessibility.
Stemson Therapeutics will start human trials for hair cloning in late 2025-2026. Product development is complete, and they are preparing for production and clinical trials.
The conversation discusses the progress and potential of hair cloning by Stemson Therapeutics, questioning if it will be realized in the next 5-10 years or if it's just false hope. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.
Hair loss can be treated by correcting glucose metabolism in hair follicles and using equol as a safer DHT blocker. Production of these treatments is starting soon, and a Discord channel is available for more information.
Phase II for TDM-105795 for Androgenic Alopecia is set to begin in April 2023. The study aims to evaluate the efficacy and safety of TDM-105795 in male subjects.
The conversation discusses hair loss treatments, including Minoxidil, finasteride, and RU58841. It highlights an interview with Stemson Therapeutics CEO Geoff Hamilton about advancements in hair cloning technology.
IGFBP‐rP1 shows potential for treating androgenic alopecia by influencing hair cycle transitions. Increasing IGF-1 levels may have similar effects to Minoxidil and 5-AR inhibitors in reducing hair loss.
Yunce Medical, a Chinese company, is developing hair multiplication technology similar to Stemson Therapeutics, with potential for quicker availability due to favorable regulations. Users express skepticism and hope for future advancements in hair loss treatments.
Hair cloning trials by Stempsen Therapeutics and Hairclone have no updates, and it may take at least 15 years for hair cloning to be available. The conversation also mentions treatments like Minoxidil, finasteride, and RU58841.
The conversation discusses using topical cetirizine as a treatment for androgenetic alopecia (hair loss). Specific treatments mentioned include Minoxidil, finasteride, and RU58841.
Eirion Therapeutics is recruiting for phase 1 of ET-02 in Texas, which showed promising hair growth results in non-clinical studies. ET-02 demonstrated significantly more hair growth compared to Minoxidil.
2% fucoidan alleviated AGA symptoms, promoted hair growth, and increased hair density in mice. Fucoidan is considered safe for humans as a supplement and topical skincare product, with potential therapeutic effects against AGA.